Genetico Center (Genetics and Reproductive Medicine Center, MOEX: GECO) has published an review of global markets for genetic testing of embryos for chromosomal abnormalities (PGT).
Approximately 8.9 million IVF cycles were performed in 2022 worldwide. The average annual growth rate was 5.2%. Russia’s infertility treatment using IVF is at the level of developed countries. According to the latest report of the Russian Association of Human Reproduction, 148.6 thousand IVF cycles were performed in 2020.
Preimplantation genetic testing (PGT) means testing of embryos for chromosomal abnormalities during IVF before the embryo is transferred into the uterus. According to international studies, the use of PGT increases the effectiveness of IVF, increasing the pregnancy rate by more than 2 times. This is due to the fact that the physician does not transfer embryos that will not develop into a normal pregnancy.
In 2012, Genetico Center began implementing PGT called Embryotest in medical practice. In 2015, a few reproductive specialists and IVF centers began using this screening. Now every 12th IVF cycle in Russia is done with PGT.
According to Genetico’s Medical Director Ylizaveta Musatova: “Embryotest and PGT are generally actively used by fertility specialists. Both physicians and patients see the effectiveness of this technology. With PGT, the patient gets pregnant after 1 or 2 IVF cycles instead of 3 or 4.
Analysts estimate the volume of Russia’s PGT market at USD 13.05 million. In 2020, 8.5% of all IVF cycles in Russia were performed with PGT. The service penetration into Russia’s medical care is lower than in the USA (25%) and China (10.16%), and has growth potential. The prevalence of PGT in Russia is increasing on average by +1% annually.
In 2022, the US PGT market was estimated at USD 109 million with a potential to increase to USD 149.5 million by 2028 .
In China, the PGT market volume amounted to USD 278 million in 2022 . Chinese analysts estimate the compound annual growth rate (CAGR) at 55%. At this rate, China’s PGT market will reach USD 3,956 million by 2028 .
According to the Russian Association of Human Reproduction, over the past 7 to 10 years there has been an increase in number of both IVF cycles and IVF cycles with PGT in Russia. This means that PGT is being used more frequently every year.
For the full version of the report, please visit:
https://investors.genetico.ru/overview%20of%20international%20PGT%20markets.html
Genetico Center is a resident of Skolkovo, the Medtech Moscow Technopark of the Moscow Center for Innovative Technologies in Healthcare, a company of the Human Stem Cell Institute group (HSCI, MOEX: ISKJ). Genetico works in the field of medical genetics and genetic research, implementing into medical practice innovative solutions for the diagnosis, prevention, and treatment of genetic and socially significant diseases.
On April 25, 2023, during its IPO on the Moscow Exchange, Genetico offered 10 million shares and raised RUB 178.8 million. The order book was oversubscribed by 2.5 times. It was the first IPO in the Russian market this year. Genetico’s shares are traded in the IIM (Innovation and Investment Market) sector, the exchange sector for high-tech companies with significant growth potential. The Moscow Exchange listed Genetico’s shares as high-tech economy sector securities.